- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Computer-Aided Mammograms Increase Medicare Cost-Burden: JAMA Study
The retrospective study analyzed SEER data from 2001 through 2009, and found that the annual CAD prevalence among Medicare screening mammograms increased from 3.5% to 79.7%.
When used during mammograms on women aged 65 and older, computer-aided detection (CAD) leads to more diagnostic intervention, including biopsy, and increases the detection of in situ breast tumors, a new study shows.
"Because in situ tumors often neither grow nor progress, CAD may be leading to a lot of unnecessary breast surgery and radiation in older women who don't really have ," Dr. Joshua J. Fenton, of the University of California Davis, told Reuters Health by email.
Medicare has reimbursed CAD during screening mammography since 2001. In a prior study, Dr. Fenton and colleagues found that CAD use increases the rate of false-positive findings on screening mammography and the detection of ductal carcinoma in situ (DCIS).
Complete report on Medscape: http://bit.ly/108L6LO
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
